Mabwell(SH:688062) Mei Ri Jing Ji Xin Wen·2025-09-17 08:25Core Viewpoint - Maiwei Biotech (688062.SH) has entered into exclusive licensing and preferred stock purchase agreements with Kalexo Bio, Inc. regarding the 2MW7141 project, which is expected to positively impact the company's future performance and enhance profitability [1] Group 1: Agreements and Financial Terms - The exclusive licensing agreement allows Kalexo to develop, produce, and commercialize the licensed products globally [1] - Maiwei Biotech will receive up to $1 billion in upfront and milestone payments from Kalexo, along with low single-digit royalties [1] - The initial non-refundable upfront payment includes $12 million in cash, with additional preferred stock in Kalexo expected under certain conditions [1] Group 2: Impact on Company Performance - The transaction is anticipated to have a positive effect on Maiwei Biotech's future performance [1] - The agreements are expected to enhance the company's profitability [1]